1. Home
  2. GLUE vs FPH Comparison

GLUE vs FPH Comparison

Compare GLUE & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • FPH
  • Stock Information
  • Founded
  • GLUE 2019
  • FPH 2009
  • Country
  • GLUE United States
  • FPH United States
  • Employees
  • GLUE N/A
  • FPH N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • FPH Real Estate
  • Sector
  • GLUE Health Care
  • FPH Finance
  • Exchange
  • GLUE Nasdaq
  • FPH Nasdaq
  • Market Cap
  • GLUE 351.2M
  • FPH 390.0M
  • IPO Year
  • GLUE 2021
  • FPH 2017
  • Fundamental
  • Price
  • GLUE $4.80
  • FPH $5.68
  • Analyst Decision
  • GLUE Buy
  • FPH
  • Analyst Count
  • GLUE 2
  • FPH 0
  • Target Price
  • GLUE $13.50
  • FPH N/A
  • AVG Volume (30 Days)
  • GLUE 369.2K
  • FPH 150.3K
  • Earning Date
  • GLUE 08-07-2025
  • FPH 10-16-2025
  • Dividend Yield
  • GLUE N/A
  • FPH N/A
  • EPS Growth
  • GLUE N/A
  • FPH 46.82
  • EPS
  • GLUE 0.29
  • FPH 1.08
  • Revenue
  • GLUE $177,986,000.00
  • FPH $197,429,000.00
  • Revenue This Year
  • GLUE $83.76
  • FPH N/A
  • Revenue Next Year
  • GLUE N/A
  • FPH N/A
  • P/E Ratio
  • GLUE $16.32
  • FPH $5.28
  • Revenue Growth
  • GLUE 2990.57
  • FPH N/A
  • 52 Week Low
  • GLUE $3.50
  • FPH $3.10
  • 52 Week High
  • GLUE $12.40
  • FPH $6.71
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 51.69
  • FPH 56.60
  • Support Level
  • GLUE $4.54
  • FPH $5.51
  • Resistance Level
  • GLUE $4.93
  • FPH $5.77
  • Average True Range (ATR)
  • GLUE 0.21
  • FPH 0.14
  • MACD
  • GLUE 0.06
  • FPH 0.04
  • Stochastic Oscillator
  • GLUE 81.43
  • FPH 95.83

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its three reportable segments are Valencia, San Francisco, and Great Park. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

Share on Social Networks: